Mandatum Life Insurance Co Ltd lifted its holdings in shares of CVS Health (NYSE:CVS) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,149 shares of the pharmacy operator’s stock after purchasing an additional 921 shares during the quarter. Mandatum Life Insurance Co Ltd’s holdings in CVS Health were worth $383,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC raised its position in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 991 shares during the last quarter. Wagner Wealth Management LLC acquired a new stake in CVS Health in the 4th quarter valued at approximately $114,000. Avestar Capital LLC acquired a new stake in CVS Health in the 4th quarter valued at approximately $122,000. Bedel Financial Consulting Inc. acquired a new stake in CVS Health in the 1st quarter valued at approximately $125,000. Finally, Focused Wealth Management Inc raised its position in CVS Health by 90.5% in the 4th quarter. Focused Wealth Management Inc now owns 1,781 shares of the pharmacy operator’s stock valued at $129,000 after buying an additional 846 shares during the last quarter. 83.96% of the stock is currently owned by institutional investors.
Shares of NYSE CVS opened at $64.92 on Friday. The company has a quick ratio of 1.88, a current ratio of 2.37 and a debt-to-equity ratio of 1.59. CVS Health has a 12 month low of $60.14 and a 12 month high of $84.00. The company has a market cap of $66.00 billion, a PE ratio of 10.42, a price-to-earnings-growth ratio of 0.97 and a beta of 1.02.
CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, May 2nd. The pharmacy operator reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.09. CVS Health had a return on equity of 17.45% and a net margin of 3.59%. The company had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.77 billion. During the same period in the previous year, the company posted $1.17 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. research analysts expect that CVS Health will post 6.99 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, May 3rd. Stockholders of record on Monday, April 23rd were paid a dividend of $0.50 per share. The ex-dividend date of this dividend was Friday, April 20th. This represents a $2.00 annualized dividend and a dividend yield of 3.08%. CVS Health’s dividend payout ratio is currently 33.90%.
In other CVS Health news, Director C David Brown II bought 10,000 shares of CVS Health stock in a transaction dated Friday, May 4th. The stock was bought at an average cost of $61.99 per share, for a total transaction of $619,900.00. Following the purchase, the director now owns 101,252 shares of the company’s stock, valued at approximately $6,276,611.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.53% of the company’s stock.
A number of equities research analysts recently issued reports on CVS shares. Loop Capital set a $68.00 target price on CVS Health and gave the company a “hold” rating in a research report on Monday, May 7th. ValuEngine lowered CVS Health from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. Bank of America dropped their target price on CVS Health from $91.00 to $88.00 and set a “buy” rating on the stock in a research report on Wednesday, April 11th. Mizuho set a $95.00 target price on CVS Health and gave the company a “buy” rating in a research report on Wednesday, January 24th. Finally, Royal Bank of Canada set a $89.00 target price on CVS Health and gave the company a “buy” rating in a research report on Thursday, February 8th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $86.27.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.